Companies

Zambon Company SpA is a pharmaceutical and chemical company founded in 1906, with headquarter in Bresso (Milan), Italy. It operates directly in North and South America, Europe and Asia, with over 2,500 employees in 15 Countries and consolidated sales of 555M€ in 2008, 80% of which generated by Zambon Pharmaceuticals SpA. Zambon Pharmaceuticals SpA leading products are Fluimucil (N-Acetylcysteine); Monuril (Fosfomycin tromethamol); Spidifen (Ibuprofen arginine). Main therapeutic areas of interest for Zambon Pharmaceuticals SpA are Respiratory, Women's care and pain relief, with focus on mild-moderate diseases. The Company is developing a portfolio of product ranging from ethical prescription drugs to self-medication products. Zambon Pharmaceuticals SpA has production plants based in EU and China.

Zambon's Pharmaceuticals Corporate Licensing Department is actively looking for in-licensing of products in the Respiratory, Woman's care and Pain relief. Moreover, Zambon Pharmaceuticals SpA is looking for out-licensing core products in territories where the Company is not present with Affiliates. Zambon's current strategy is to develop a portfolio of products ranging from ethical prescription drugs to OTC products that can play a significant role in the target areas. Main medical target currently visited are: GPs, Gynaecologists, ENT, Pediatricians, Pneumologists and Pharmacies, the latter covered by specialized sales lines in all key Countries.

Zambon has three main therapeutic areas: winter illnesses, women's health care and pain relief. Three top products for the same number of areas:

FLUIMUCIL® (active principle: N-Acetylcysteine)
A mucolytic with anti-oxidant properties, used worldwide for the treatment of various acute and chronic pathologies of the respiratory system.

MONURIL® (active principle: Fosfomycin Tromethamol)
An antibiotic specific for the treatment of un-complicated urinary tract infections (cystitis). The product is active with one single administration. This makes it a convenient first choice for treatment of common urinary infections. Fosfomycin Tromethamol is also approved by the prestigious American FDA.

SPEDIFEN® (active principle: Ibuprofen Arginine)
A special form of the well known analgesic Ibuprofen salified "in-situ" with L-Arginine. The addition of L-arginine allows a faster onset of pain relief with respect to commercially available ibuprofen formulations.

Important agreement were signed in 2004:

ObeTherapy Biotechnology - an R&D collaboration agreement with the aim of identifying low-molecular weight drugs for the treatment of metabolic disorders such as dyslipidaemia, metabolic syndrome, obesity and related comorbidities.

Bioxell - a research collaboration aimed at identifying and developing small molecule drugs that antagonize CXCR3, a chemokine receptor protein which plays a key role inflammatory diseases affecting skin, joints as well as the respiratory and gastrointestinal tract

Newron Pharmaceutical - a collaboration and liccence agreement aimetd at discovering, developing and commercializing novel compounds active as sodium and calcium channel blockers for the treatment of pain conditions, a growing market of unmet medical need

Paola Corna Pellegrini (General Manager, Pharma Business and Zambo Italy)